阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

休市中 10-16 16:00:00 EDT

165.41

-1.27

-0.76%

盘后164.21

-1.20-0.73%

19:45 EDT

最高167.18	最低164.37	成交量346.16万
今开166.97	昨收166.68	日振幅1.69%
总市值2,566亿	流通市值2,479亿	总股本15.51亿
成交额5.73亿	换手率0.23%	流通股本14.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":165.41,"timestamp":1792180800000,"preClose":166.68,"halted":0,"volume":3461584,"hourTrading":{"tag":"盘后","latestPrice":164.21,"preClose":165.41,"latestTime":"19:45 EDT","volume":129874,"amount":21481462.0733,"timestamp":1792194352460,"change":-1.2,"changeRate":-0.007255,"amplitude":0.007678},"delay":0,"changeRate":-0.00761939044876416,"floatShares":1498932637,"shares":1551000000,"eps":6.679974,"marketStatus":"休市中","change":-1.27,"latestTime":"10-16 16:00:00 EDT","open":166.97,"high":167.18,"low":164.365,"amount":573354100.3848001,"amplitude":0.016889,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.679974,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":7,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":166.68,"dividendRate":0.019146,"preHourTrading":{"tag":"盘前","latestPrice":166.96,"preClose":166.68,"latestTime":"09:29 EDT","volume":27215,"amount":4530575.7582,"timestamp":1792157399999,"change":0.28,"changeRate":0.00168,"amplitude":0.008339},"postHourTrading":{"tag":"盘后","latestPrice":164.21,"preClose":165.41,"latestTime":"19:45 EDT","volume":129874,"amount":21481462.0733,"timestamp":1792194352460,"change":-1.2,"changeRate":-0.007255,"amplitude":0.007678},"volumeRatio":1.093508554944464,"impliedVol":0.3584,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"1160526008","title":"美股异动｜美股药品制造商板块逆市走强，阿斯利康、施贵宝、礼来涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160526008","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160526008?lang=zh_cn&edition=full","pubTime":"2026-10-15 22:07","pubTimestamp":1792073252,"startTime":"0","endTime":"0","summary":"美股药品制造商板块逆市走强，阿斯利康、施贵宝、礼来涨超4%，葛兰素史克、诺和诺德、诺华制药涨超3%，强生、辉瑞、默沙东、艾伯维涨超2%。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","LLYX","ELIL","ELIS","AZN","BMY","LLII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168537584","title":"异动解读｜阿斯利康盘中上涨3.75%，签署AI药物发现合作强化研发预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1168537584","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168537584?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:36","pubTimestamp":1792071363,"startTime":"0","endTime":"0","summary":"10月15日，阿斯利康盘中上涨3.75%，报169.2美元，成交额6256.32万美元。消息面上，公司宣布与AI药物研发企业insitro达成药物发现与授权合作，围绕MASH及心肌病等领域推进靶点识别，提振市场对其前沿研发能力的预期。根据协议，insitro将获得4000万美元首付款，并有资格取得最高14.6亿美元开发及商业化里程碑付款，另享全球销售个位数比例特许权使用费；阿斯利康则获得相关项目在探索及早期开发后续阶段的全球独家商业化权益。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康盘中上涨，签AI药物合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166247508","title":"异动解读｜阿斯利康盘前上涨3.07%，签署AI药物发现合作强化研发预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166247508","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166247508?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:38","pubTimestamp":1792067916,"startTime":"0","endTime":"0","summary":"10月15日，阿斯利康盘前上涨3.07%，报166.99美元，成交额394.54万美元。消息面上，公司宣布与AI药物研发企业insitro达成药物发现与授权合作，围绕MASH及心肌病等领域利用其虚拟人AI平台识别药物靶点，强化市场对其前沿研发能力的预期。根据协议，insitro将获得4000万美元首付款，并有资格取得最高14.6亿美元开发及商业化里程碑付款，另享全球销售个位数比例特许权使用费；阿斯利康则获得相关项目在探索及早期开发后续阶段的全球独家商业化权益。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康盘前上涨，携手AI药企加速研发","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582520","title":"阿斯利康（AZN）与insitro达成药物发现与授权合作协议 深化AI药物研发布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582520","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582520?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:18","pubTimestamp":1792066738,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康（AZN）宣布，已与总部位于加州的AI药物研发公司insitro达成一项药物发现与授权合作协议。根据协议，双方将利用insitro旗下的“虚拟人”AI平台共同识别药物靶点，重点攻克代谢功能障碍相关脂肪性肝炎（MASH）及心肌病等领域尚未满足的临床需求。阿斯利康将获得获选项目在探索及早期开发阶段后的全球独家商业化权益。作为交易回报，insitro将获得4000万美元的首付款，以及最高可达14.6亿美元的开发与商业化里程碑付款，未来还将按全球销售额提取个位数百分比的特许权使用费。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307238","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","IBBJ","LU2237443465.HKD","LU2468319806.SGD","LU2089984988.USD","LU0128525929.USD","LU0708994859.HKD","LU0320765992.SGD","VTHR","LU2237443895.HKD","BK4568","ARTY","LU2237443549.SGD","AZN","LU2237443382.USD","LU0889565916.HKD","LU2417539215.USD","LU0289739699.SGD","LU0058720904.USD","LU0310800379.SGD","LU1829250122.USD","IE00B3T34201.USD","LU0432979614.USD","LU2456880835.USD","AZNH","LU2236285917.USD","CHAT","BK4007","AGIX","LU2237443622.USD","LU0029864427.USD","BK4585","BK4588","LU2237443978.SGD","LU1267930573.SGD","LU2462157665.USD","LU0109394709.USD","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176297515","title":"异动解读｜阿斯利康盘中上涨3.11%，乳腺癌药物Datroway中国获批后催化情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1176297515","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176297515?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:47","pubTimestamp":1791985621,"startTime":"0","endTime":"0","summary":"10月14日，阿斯利康盘中上涨3.11%，报160.69美元，成交额5130.28万美元。近日消息面上，阿斯利康与第一三共联合开发的乳腺癌药物Datroway获中国批准，成为本轮股价异动的核心催化。该批准基于一项Ⅲ期试验：Datroway将中位总生存期由化疗的18.7个月提升至23.7个月，并将疾病进展或死亡风险降低43%；其中中位无进展生存期为10.8个月，高于化疗的5.6个月。对阿斯利康而言，这延续了其近期肿瘤管线在乳腺癌领域的审批与临床进展。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康盘中上涨，乳腺癌新药获批催化情绪","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127495731","title":"阿斯利康将向 Summit Therapeutics 投资 20 亿美元，合作开发癌症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1127495731","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127495731?lang=zh_cn&edition=full","pubTime":"2026-09-29 07:48","pubTimestamp":1790639306,"startTime":"0","endTime":"0","summary":"Summit Therapeutics周一表示，英国制药公司阿斯利康将向该公司投资 20 亿美元，并合作开展一系列研究，测试双方的癌症治疗药物联合使用的效果。该消息公布后，Summit 股价在盘后交易中上涨超过 17%。此次投资体现了阿斯利康对 ivonescimab这一下一代癌症治疗药物的高度信心。Summit 此前从Akeso获得了该药物的授权。Ivonescimab 的作用机制是同时阻断 PD-1 和 VEGF。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康将向 Summit Therapeutics 投资 20 亿美元，合作开发癌症药物","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669745163","title":"从倾听到回应：阿斯利康携手多方力量，共塑以患者为中心的癌症诊疗未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2669745163","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669745163?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:36","pubTimestamp":1789979760,"startTime":"0","endTime":"0","summary":"通过PALS以及中国肿瘤诊疗变革患者顾问委员会，我们希望凝聚多方智慧和力量，增进共识、深化合作，将患者洞察转化为有意义的行动，共同塑造更加以患者为中心的肿瘤诊疗未来。阿斯利康中国肿瘤业务总经理关冬梅表示：\"患者正逐步成长为推动癌症诊疗变革的重要参与者。本次交流会标志着阿斯利康中国在推动\"以患者为中心\"的癌症诊疗体系建设方面迈出了重要一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5052430_ZH52430_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5052430_ZH52430_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0432979614.USD","BK4588","BK4568","LU2237443549.SGD","LU0109394709.USD","LU0708994859.HKD","LU2237443895.HKD","LU2236285917.USD","LU2462157665.USD","LU0289739699.SGD","LU2468319806.SGD","LU2456880835.USD","LU1267930573.SGD","IE00B3T34201.USD","IBBQ","AZNH","BK4585","LU0058720904.USD","LU0310800379.SGD","LU2237443622.USD","BK4007","LU2237443465.HKD","LU2417539215.USD","LU2237443382.USD","LU0128525929.USD","LU1829250122.USD","AZN","LU0889565916.HKD","LU2237443978.SGD","LU0029864427.USD","LU0320765992.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668504920","title":"FLAURA2 III期临床研究中国人群亚组OS数据显示 泰瑞沙联合化疗一线治疗EGFR突变晚期非小细胞肺癌总生存期获益趋势与全球保持一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2668504920","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668504920?lang=zh_cn&edition=full","pubTime":"2026-09-18 21:48","pubTimestamp":1789739280,"startTime":"0","endTime":"0","summary":"OS是评估肿瘤患者生存获益的\"金标准\"，此次中国人群OS数据的公布，为该方案在中国EGFR突变晚期肺癌患者中的长生存获益提供了循证依据，进一步证实奥希替尼联合化疗可成为一线标准治疗选择。晚期患者中，奥希替尼在FLAURA III期研究中作为单药疗法，以及在FLAURA2 III期研究中联合化疗，均显示出临床结局改善。作为阿斯利康持续承诺治疗早期肺癌的重要组成部分，ADAURA2 III期临床研究正在进行中，评估奥希替尼用于早期可切除EGFRm NSCLC的辅助治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5051447_ZH51447_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5051447_ZH51447_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2236285917.USD","BK4588","LU0109394709.USD","BK4568","LU0310800379.SGD","AZNH","BK4211","BK4195","BK4007","LU0320765992.SGD","LU2237443465.HKD","LU2462157665.USD","LU2237443895.HKD","LU2468319806.SGD","LU2456880835.USD","LU0708994859.HKD","LU1829250122.USD","LU2237443382.USD","LU0058720904.USD","LU0029864427.USD","LU0289739699.SGD","LU0432979614.USD","LU2417539215.USD","AZN","LU2089984988.USD","LU2237443549.SGD","LU0889565916.HKD","LU0128525929.USD","BK4585","PFS","LU1267930573.SGD","LU2237443622.USD","LU2237443978.SGD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668692526","title":"阿斯利康（AZN）与第一三共联合研发ADC药物Enhertu®获欧盟CHMP推荐批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2668692526","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668692526?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:33","pubTimestamp":1789734792,"startTime":"0","endTime":"0","summary":"金吾财讯 | 9月18日消息，欧洲药品管理局 人用药品委员会出具积极意见，推荐批准由第一三共与阿斯利康联合开发的ADC药物Enhertu，用于新辅助治疗后仍有残留浸润性病灶的高危HER2阳性早期乳腺癌成年患者的辅助治疗。结果显示，与现有标准疗法T-DM1相比，Enhertu将患者的浸润性疾病复发或死亡风险大幅降低了53%，三年无浸润性疾病生存率达到92.4%。目前该意见已提交欧盟委员会进行最终上市许可审批，若顺利获批，Enhertu有望重塑欧洲早期乳腺癌术后治疗标准。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306231","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","BK4568","CHMP","LU2089984988.USD","LU0109394709.USD","LU2468319806.SGD","LU0128525929.USD","LU2237443978.SGD","LU0289739699.SGD","LU1829250122.USD","BK4087","AZN","BK4585","LU2237443622.USD","LU2237443465.HKD","LU0310800379.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0708994859.HKD","LU1267930573.SGD","LU0432979614.USD","LU0029864427.USD","LU2462157665.USD","IE00B3T34201.USD","LU2417539215.USD","AZNH","FSXEmain","BK4588","BK4007","LU2456880835.USD","LU2237443549.SGD","LU0058720904.USD","LU2237443895.HKD","LU2237443382.USD","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115044656","title":"异动解读｜阿斯利康盘后下跌3.65%，报154.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115044656","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115044656?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:33","pubTimestamp":1789158806,"startTime":"0","endTime":"0","summary":"9月12日，阿斯利康盘后下跌3.65%，报154.61美元/股，成交额244.99万美元。阿斯利康所在的制药行业中，个股中，礼来涨0.11%，默沙东跌0.02%，强生涨0.34%，辉瑞跌0.1%，诺和诺德持平。阿斯利康股份有限公司于1992年根据《公司法》在英格兰和威尔士注册成立，1999年与瑞典Astra公司合并。公司主营业务覆盖肿瘤、呼吸、罕见病等多个治疗领域，2007年收购美国生物制剂企业MedImmune，2021年收购罕见病企业Alexion。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安进（AMGN）联合疗法III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666712586?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","IE00B4R5TH58.HKD","IBB","LU1571399168.USD","LU0122379950.USD","LU2237443895.HKD","LU2237443622.USD","IE00B2B36J28.USD","LU1829250122.USD","LU2242652126.USD","SG9999001440.SGD","IBBQ","LU0708994859.HKD","LU0289739699.SGD","PBE","LU2237443382.USD","LU0109394709.USD","LU0432979614.USD","LU0029864427.USD","LU1023059063.AUD","LU2242646821.SGD","LU2237443978.SGD","LU2089984988.USD","BK4581","LU2456880835.USD","BIB","LU2112291526.USD","LU2236285917.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","BK4599","LU1267930573.SGD","BK4139","AZNH","BK4568","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4566","AZN","BK4533","TBXU","LU2462157665.USD","BK4534","IE0002141913.USD","BK4585","LU0868494617.USD","PJP","LU2468319806.SGD","AMGN","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665968376","title":"Tozorakimab在OBERON和TITANIA两项Ⅲ期临床试验中，在降低慢阻肺病急性加重方面均显示出统计学和临床意义上的显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2665968376","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665968376?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:18","pubTimestamp":1788873480,"startTime":"0","endTime":"0","summary":"OBERON和TITANIA两项Ⅲ期试验的结果令人鼓舞，证实tozorakimab在广泛患者人群中均能降低急性加重风险，有望帮助患者摆脱反复急性加重的困扰，获得全新的治疗选择。Tozorakimab 是首个在广泛慢阻肺病患者人群中显示出减少气道黏液栓堵塞作用的生物制剂3。Tozorakimab总体耐受性和安全性良好，唯一报告的药物不良反应为注射部位反应1,2。目前，tozorakimab已在欧盟、中国等主要市场进入上市许可审评阶段，用于治疗慢性阻塞性肺疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","AZN","LU0310800379.SGD","LU2237443549.SGD","BK4007","LU0128525929.USD","LU2236285917.USD","BK4588","IBBQ","BMED","LU1267930573.SGD","LU1829250122.USD","LU2237443382.USD","LU2237443895.HKD","LU0109394709.USD","IBBJ","LU2089984988.USD","LU2237443465.HKD","LU2468319806.SGD","LU0320765992.SGD","BK4568","LU0432979614.USD","LU0889565916.HKD","AZNH","MDTX","LU2237443978.SGD","LU2456880835.USD","LU0029864427.USD","IE00B3T34201.USD","LU2417539215.USD","LU0058720904.USD","LU0708994859.HKD","LU2462157665.USD","PSYK","LU2237443622.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341019","title":"商务部新增84个全国重点外资项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341019","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665341019?lang=zh_cn&edition=full","pubTime":"2026-09-08 12:05","pubTimestamp":1788840300,"startTime":"0","endTime":"0","summary":"【大河财立方记者程帅星厦门报道】9月8日，大河财立方记者在第二十六届中国国际投资贸易洽谈会(以下简称“投洽会”)上获悉，商务部近日新增84个全国重点外资项目，其中包括6个外资标志性项 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260908/c679692496.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260908/c679692496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["SG9999001176.SGD","LU1623119135.USD","LU1023059063.AUD","LU0819121731.USD","LU1868836591.USD","LU0266013472.USD","LU0058720904.USD","LU1035775433.USD","SKDD","IE00BJJMRZ35.SGD","LU1804176565.USD","LU2361044949.HKD","BK4581","LU0210536198.USD","LU0820561818.USD","LU0889565916.HKD","LLII","LU2087625088.SGD","IE0002141913.USD","SKHN","LU0079474960.USD","SG9999015978.USD","LU2456880835.USD","LU1720051108.HKD","LU2237443465.HKD","LU0471298777.SGD","LU0203201768.USD","IE00BJT1NW94.SGD","LU1868836914.USD","LU2237443895.HKD","LU2236285917.USD","LU0198837287.USD","LU0052750758.USD","SKHYV","SK","LU0456846285.SGD","LU1548497426.USD","BK4588","LU1232071149.USD","PJP","LU2039709279.SGD","SKHL","LU1974910355.USD","LU2491050154.USD","LU0787776722.HKD","LU0964807845.USD","LU0588546209.SGD","LU0106261372.USD","BK4533","LU0708995401.HKD","LU0683600562.USD","LU0323591593.USD","GDOC","ELIS","LU0516423174.USD","LU0327786744.USD","LU2324357040.USD","SG9999002463.SGD","LU2357305700.SGD","LU2462157665.USD","SG9999002562.SGD","LU2417539215.USD","LU0979878070.USD","LU0466842654.USD","LU1057294990.SGD","SG9999001176.USD","BK4096","CANC","LU1366192091.USD","LU0039217434.USD","IE00B3T34201.USD","LU1794554557.SGD","LU1093756325.SGD","LU2328871848.SGD","LU0786609619.USD","LU2471134796.USD","SG9999015952.SGD","LU0820561909.HKD","LU2237443622.USD","BK4534","LU2471134879.HKD","LU1868837136.USD","LU0051755006.USD","LU0354030438.USD","LU1917777945.USD","LU1868837300.USD","LU2552382058.USD","SG9999014880.SGD","AZN","IE00BFSS8Q28.SGD","TRUH","IE00B7KXQ091.USD","LU0307460666.USD","LU0096364046.USD","LU1267930573.SGD","LU0181495838.USD","LU2237438978.USD","LU2461242641.AUD","LU0359201612.USD","LU2112291526.USD","SG9999018857.SGD","LU0823397103.USD","VHT","LU2361045086.USD","IE00BN29S564.USD","LU2462591350.SGD","LU2360106947.USD","LU1069344957.HKD","LU2211815571.USD","IE00BJJMRX11.SGD","BK0187","LU0203202063.USD","FHLC","LU0823426480.USD","SG9999014914.USD","LU1712237335.SGD","LU2237443382.USD","LU2746668974.SGD","LU2552382215.SGD","LU1061106388.HKD","BK4516","XLV","LU1093756168.USD","LU1983299246.USD","BK1576","LU2750360997.AUD","IE0001KFT4U8.USD","07709","LU0882574139.USD","LU0316494557.USD","LU0432979614.USD","LU0823434740.USD","SKHZ","KURE","SG9999013999.USD","IE0004445239.USD","LU0128525929.USD","LU2168563687.JPY","IE00BKDWB100.SGD","LU2063271972.USD","LU0708995583.HKD","LU0109391861.USD","LU0353189680.USD","LU0320765992.SGD","SKHU","LU0140636845.USD","LU0823413587.USD","LU0320764599.SGD","LU0061475181.USD","SG9999017495.SGD","LU0417516902.SGD","002493","IE0005OL40V9.USD","HRTS","LU0238689110.USD","IE00BKPKM429.USD","LU0823397285.USD","LU2468319806.SGD","BK0196","BK4568","LU0516422366.SGD","BK4007","LU0006306889.USD","LU2271345857.HKD","LU2168564065.EUR","FTXH","LU0225283273.USD","LU2265009873.SGD","BK4141","IE00BK4W5L77.USD","LU1280957306.USD","MEDX","LU0417516738.SGD","LU0289739699.SGD","LU0310800379.SGD","IHE","LU0456827905.SGD","LU1814569148.SGD","THNR","LU2491050071.SGD","LU1551013425.SGD","SG9999014906.USD","SKHY","LU0256863811.USD","LU0326950275.SGD","BK4599","IE0009355771.USD","SKHX","BK1521","LU0708994859.HKD","LU2264538146.SGD","LU0353189763.USD","LU2602419157.SGD","LU1242518857.USD","LU2168564222.USD","LU0128526141.USD","LU0516422952.EUR","JDOC","LLYX","LU0174119429.USD","LU0354030511.USD","LU0043850808.USD","MEDI","ILDR","LU2168564149.EUR","LU0345770308.USD","IYH","LU0385154629.USD","LLY","LU0823416689.USD","LU1267930730.SGD","LU0114720955.EUR","LU2028103732.USD","LU2471134952.CNY","IE00BFSS7M15.SGD","BK1589","SGXZ99366536.SGD","LU0320765059.SGD","IE00B1XK9C88.USD","IE00BFTCPJ56.SGD","LU2089283258.USD","LU1291159041.SGD","LU2108987350.USD","LU1323610961.USD","LU2023251221.USD","LU0640476718.USD","LU0823434583.USD","ABB","SGXZ81514606.USD","MHIP","IE00B0JY6N72.USD","WDNA","BK0197","SG9999015986.USD","LU0882574055.USD","BK1610","LU1868836757.USD","SKHA","LU2111349929.HKD","LU0348735423.USD","LU2552382132.HKD","AGNG","LU0471298694.HKD","LU0516423091.SGD","LU2750360641.GBP","LU1688375341.USD","LU2471134523.USD","BK0028","LU2746668461.USD","SKUU","BK0208","LU2756315318.SGD","LU2213496289.HKD","LU0029874061.USD","SKHQ","LU1969619763.USD","OZEM","AZNH","LLYZ","PPH","LU0820562030.AUD","IE00B4R5TH58.HKD","LU0823413660.USD","BK4585","LU0856984785.SGD","LU1988902786.USD","LU2237443549.SGD","SGXZ57979304.SGD","LU1989771016.USD","LU1629891620.HKD","LU3063872942.SGD","IXJ","LU1127390331.HKD","SGXZ51526630.SGD","LU1720050803.USD","RXL","LU1880383366.USD","IE00BWXC8680.SGD","IE00B4JS1V06.HKD","IE00BK4W5M84.HKD","WXXWY","IE00B1BXHZ80.USD","LU2106854487.HKD","LU1064131342.USD","LU0029864427.USD","LU0516422440.USD","LU0234572021.USD","LU0094547139.USD","LU0417517546.SGD","ELIL","TMED","LU1242518931.SGD","LU1145028129.USD","LU2023250330.USD","LU2168564495.EUR","IE00B775H168.HKD","LU2023250504.SGD","LU0097036916.USD","LU0158827781.USD","LU0348825331.USD","IE00BJJMRY28.SGD","LU0672654240.SGD","SG9999015945.SGD","LU0133085943.USD","IE0004445015.USD","LU2491049909.HKD","LU2756315664.SGD","LU2237443978.SGD","SGXZ31699556.SGD","HYNX","LU2361044865.SGD","LU2896262040.SGD","CURE","LU1956131251.USD","SG9999014898.SGD","LU1551013342.USD","LU0109394709.USD","GB00BDT5M118.USD","LU0572944931.SGD","LU2089284900.SGD","LU1720051017.SGD","IE00BJLML261.HKD","LU0943347566.SGD","IE00B2B36J28.USD","LU0823426308.USD","LU1829250122.USD","BK1141","LU0158827948.USD","LU0345770993.USD","02269","BK0188","LU1691799644.USD","LU0456855351.SGD","LU0256863902.USD","LU1979441026.SGD","LU0122379950.USD","LU0359202008.SGD","LU0689472784.USD","SG9999018865.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665935968","title":"美国食品药品监督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用于治疗伴有ESR1突变的晚期乳腺癌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935968","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665935968?lang=zh_cn&edition=full","pubTime":"2026-09-05 03:47","pubTimestamp":1788551256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0432979614.USD","AZNH","159151","LU0029864427.USD","LU0128525929.USD","LU0289739699.SGD","LABU","LU2417539215.USD","LU0310800379.SGD","LU0109394709.USD","LU2468319806.SGD","LU2237443622.USD","LU2462157665.USD","AZN","LU2089984988.USD","IE00B3T34201.USD","LU0708994859.HKD","LU2236285917.USD","LU1267930573.SGD","BK4007","LU0320765992.SGD","LU2237443978.SGD","BK4585","LU2237443549.SGD","BK4568","LU0058720904.USD","LU2456880835.USD","LU2237443465.HKD","LU2237443895.HKD","BK4588","LU0889565916.HKD","LU1829250122.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664368853","title":"阿斯利康（AZN）抗体偶联药物Enhertu联合疗法获欧盟新适应症批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664368853","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664368853?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:36","pubTimestamp":1788258974,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康 与第一三共联合宣布，其抗体偶联药物Enhertu联合帕妥珠单抗的组合疗法已正式获得欧盟委员会批准，用于一线治疗不可切除或转移性HER2阳性乳腺癌成年患者。这也是Enhertu在短短两个月内于欧盟获得的第二个新适应症批准。随着这一欧盟监管决定的落地，阿斯利康将向第一三共支付1亿美元的里程碑付款。目前，该疗法已在包括美国、中国在内的全球40多个国家和地区获批上市。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305553","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU2468319806.SGD","LU2089984988.USD","LU0128525929.USD","LU0708994859.HKD","LU0320765992.SGD","LU2237443895.HKD","BK4568","LU2237443549.SGD","AZN","LU2237443382.USD","FSXEmain","LU0889565916.HKD","LU2417539215.USD","LU0289739699.SGD","LU0058720904.USD","LU0310800379.SGD","LU1829250122.USD","IE00B3T34201.USD","LU0432979614.USD","LU2456880835.USD","AZNH","LU2236285917.USD","BK4007","LU2237443622.USD","LU0029864427.USD","BK4585","BK4588","FESXmain","LU2237443978.SGD","LU1267930573.SGD","LU2462157665.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167412971","title":"异动解读｜阿斯利康夜盘下跌4.14%，多重管线挫折与竞争压力持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1167412971","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167412971?lang=zh_cn&edition=full","pubTime":"2026-09-01 15:02","pubTimestamp":1788246168,"startTime":"0","endTime":"0","summary":"9月1日，阿斯利康夜盘下跌4.14%，报155.42美元/股，成交额39.88万美元。近期阿斯利康面临多重负面因素叠加。竞争层面，Summit此前公布的依沃西单抗III期试验数据显示疗效优于阿斯利康核心肿瘤药Imfinzi，直接冲击其肿瘤免疫治疗市场地位。技术面上，阿斯利康股价近一个月已累计下跌逾5%，处于横盘偏弱格局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"阿斯利康夜盘下挫，肿瘤管线屡遭挫折","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662671167","title":"疗效碾压阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西单抗III期试验数据积极，股价应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2662671167","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662671167?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:32","pubTimestamp":1787747523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2456880835.USD","LU0029864427.USD","LU0889565916.HKD","LU2417539215.USD","BK4007","LU2488822045.USD","LU2089984988.USD","LU2237443382.USD","LU2237443622.USD","LU0058720904.USD","III","AZN","LU2237443465.HKD","BK4588","LU0289739699.SGD","LU2468319806.SGD","SMMT","IE00B3T34201.USD","LU0320765992.SGD","LU0432979614.USD","BK4568","LU2462157665.USD","LU0708994859.HKD","AZNH","LU0109394709.USD","LU2237443895.HKD","LU1829250122.USD","LU1267930573.SGD","BK4585","LU2237443978.SGD","LU0128525929.USD","LU2236285917.USD","LU2237443549.SGD","BK4139","LU0310800379.SGD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662097761","title":"国药控股与阿斯利康启动基药惠民专项合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2662097761","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662097761?lang=zh_cn&edition=full","pubTime":"2026-08-26 11:23","pubTimestamp":1787714595,"startTime":"0","endTime":"0","summary":"南方财经8月26日电，据国药控股消息，近日，国药控股与阿斯利康在上海召开高层战略合作交流会，并正式启动基药惠民专项合作。阿斯利康作为国药控股核心战略合作伙伴，双方在医药流通、创新服务、民生惠民等多个核心领域已形成深度协作。此次项目启动，标志着聚焦国家基药政策落地与基层医疗可及性提升，双方合作已向更深层次、更广领域迈进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854365220.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854365220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0432979614.USD","LU2237443382.USD","BK4588","LU2417539215.USD","LU2468319806.SGD","LU0128525929.USD","LU2237443465.HKD","AZNH","BK1197","BK4568","LU0029864427.USD","BK4585","LU1115378108.SGD","LU2237443978.SGD","LU2462157665.USD","LU0640798160.USD","LU0109394709.USD","IE00B3T34201.USD","LU0320765992.SGD","LU0289739699.SGD","LU1829250122.USD","BK1500","LU2089984988.USD","LU2237443895.HKD","LU2237443622.USD","LU2237443549.SGD","LU2456880835.USD","LU1267930573.SGD","01099","LU0058720904.USD","BK1515","LU0310800379.SGD","LU0889565916.HKD","BK4007","AZN","LU2236285917.USD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660917282","title":"迪哲医药上半年营收破5亿，已与阿斯利康达成舒沃替尼全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2660917282","media":"新浪财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660917282?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:55","pubTimestamp":1787230500,"startTime":"0","endTime":"0","summary":"8月20日，迪哲医药发布2026半年报，报告期内，公司实现营业收入5.23亿元，较上年同期增长47%。7月，迪哲医药与阿斯利康签署舒沃替尼的全球独家许可协议，授予阿斯利康在全球范围内独家开发、商业化舒沃替尼的权利。根据协议条款，迪哲医药将获得一次性、不可返还首付款6亿美元，最高达4亿美元的临床开发里程碑款项及最高达5亿美元的销售里程碑款项；此外，还将获得按舒沃替尼全球销售额阶梯式比例的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-20/doc-ininynce7991209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","09939","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286748","title":"阿斯利康长效C5补体抑制剂伟立瑞获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286748","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660286748?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:58","pubTimestamp":1787223480,"startTime":"0","endTime":"0","summary":"南方财经8月20日电，记者获悉，阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞?（英文商品名：Ultomiris?，通用名：瑞利珠单抗注射液），已获得中国国家药品监督管理局（NMPA）批准，用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症（PNH）患者的治疗。PNH是一种慢性、进行性且危及生命的血液系统罕见疾病。该疾病好发于青壮年，77%的PNH患者在20-40岁发病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847950261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847950261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2237443382.USD","LU0889565916.HKD","LU1829250122.USD","LU2237443895.HKD","IPOS","AZNH","LU0109394709.USD","LU0320765992.SGD","LU2468319806.SGD","LU0029864427.USD","LU2237443465.HKD","LU2236285917.USD","BK4568","LU0289739699.SGD","LU2237443549.SGD","LU0432979614.USD","LU2462157665.USD","LU2237443622.USD","LU2456880835.USD","LU1267930573.SGD","LU2417539215.USD","LU2237443978.SGD","LU2089984988.USD","LU0128525929.USD","LU0310800379.SGD","BK4588","IE00B3T34201.USD","LU0058720904.USD","LU0708994859.HKD","AZN","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.039},{"period":"1month","weight":0.0155},{"period":"3month","weight":-0.0207},{"period":"6month","weight":-0.1923},{"period":"1year","weight":-0.0134},{"period":"ytd","weight":-0.1003}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008212},{"month":6,"riseRate":0.470588,"avgChangeRate":0.018421},{"month":7,"riseRate":0.588235,"avgChangeRate":-0.005538},{"month":8,"riseRate":0.470588,"avgChangeRate":0.003346},{"month":9,"riseRate":0.529412,"avgChangeRate":0.001076},{"month":10,"riseRate":0.558824,"avgChangeRate":0.015568},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}